How Vildagliptin Improves Time in Range in T2DM patients ft-Prof. Dr Aravinda Jagadeesha

Several studies have also demonstrated that Vildagliptin affords better circadian glucose control and lower glycemic variability with better Time in Range than sitagliptin, mainly driven by a reduction in basal hyperglycaemia.

Vildagliptin is typically used in combination with metformin but can also be used concurrently with empagliflozin, sulfonylurea, pioglitazone or basal insulin.

Several studies have documented that in people with type 2 diabetes who are already taking metformin, adding vildagliptin once or twice daily to their treatment regimen reduces HbA1c levels by a further 7 – 12 mmol/mol after 12 weeks of treatment. When vildagliptin is used alone in people who do not tolerate metformin, it reduces HbA1c levels by an average of 6 – 9 mmol/mol. This is in line with the current diabetes treatment programs which aim at lowering HbA1c levels.

This points up the benefit of the early addition of Vildagliptin to metformin without waiting for glucose control to further deteriorate while not exposing patients to an increased risk of hypoglycaemia-